Posterior semicircular canal BPPV
Conditions
Interventions
Control group:Betastine mesylate tablets are taken orally after meals, 6 mg tid, for 2 weeks
joint group:Betastine mesylate tablets orally after meals, 6mg, tid vinblastine extended-release capsules orally after meals, 30mg, bid, for 2 weeks
Sponsors
Yongchuan District People's Hospital
Chongqing, China
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Diagnosed with posterior canal BPPV and having successful repositioning, yet presenting with persistent residual dizziness (DHI score = 20); aged 18–70 years.
Exclusion criteria
Exclusion criteria: (1) Patients unable to cooperate with the examiner for canalith repositioning procedures due to intellectual disability or other reasons; (2) Patients with other underlying causes (e.g., posterior circulation ischemia, Ménière's disease, sudden sensorineural hearing loss, vestibular neuritis, vestibular migraine, etc.); (3) Patients with comorbidities including severe cardiac disease, cervical/lumbar spondylosis, pregnancy, active peptic ulcer, reflux esophagitis, bronchospasm, asthma, chronic obstructive pulmonary disease (COPD), pheochromocytoma, hepatic/renal insufficiency, elevated intracranial pressure, acute phase of cerebrovascular hemorrhage, severe electrolyte imbalance, or QT interval prolongation; (4) Patients with hypersensitivity to the study agents.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dizziness Handicap Inventory;European Evaluation Scale for Vertigo;Video head pulse test; | — |
Countries
China
Contacts
Public Contactluyuqing
Yongchuan District People's Hospital Chongqing, China
Outcome results
None listed